4 results on '"Richter, A."'
Search Results
2. Cost of youth tobacco-control policies in seven European countries.
- Author
-
Leão, Teresa, Perelman, Julian, Clancy, Luke, Hoffmann, Laura, Kinnunen, Jaana M, Mélard, Nora, Nuyts, Paulien A W, Richter, Matthias, Rimpelä, Arja, Lorant, Vincent, and Kunst, Anton E
- Subjects
- *
HEALTH policy , *ECONOMICS , *SMOKING prevention , *HEALTH education , *HEALTH promotion , *PUBLIC health , *SCHOOL health services , *SMOKING , *TOBACCO , *COST analysis , *GOVERNMENT policy , *HUMAN services programs , *RETROSPECTIVE studies , *ADOLESCENCE ,ADVERTISING & economics - Abstract
Background Tobacco-control policies have been suggested to reduce smoking among adolescents. However, there is limited evidence on the real-world costs of implementation in different settings. In this study, we aimed at estimating the costs of school smoking bans, school prevention programmes and non-school bans (smoking bans in non-educational public settings, bans on sales to minors and bans on point-of-sale advertising), implemented in Finland, Ireland, the Netherlands, Belgium, Germany, Italy and Portugal, for 2016. Methods We retrospectively collected costs related to the inspection, monitoring and sanctioning activities related to bans and educational activities related to smoking prevention programmes. We used an 'ingredients-based' approach, identifying each resource used, quantity and unit value for one full year, under the state perspective. Costs were measured at national, regional, local and school-level and were informed by data on how these activities were performed in reality. Results Purchasing power parities adjusted-costs varied between €0.02 and €0.74 (average €0.24) per person (pp) for bans implemented outside schools. Mean costs of school smoking bans ranged from €3.31 to €34.76 (average €20.60), and mean costs of school educational programmes from €0.75 to €4.65 (average €2.92). Conclusions It is feasible to estimate costs of health policies as implemented in different settings. Costs of the tobacco control policies evaluated here depend mainly on the number of person-hours allocated to their implementation, and on the scale of intervention. Non-school bans presented the lowest costs, and the implementation of all policies cost up to €36 pp for 1 year. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.
- Author
-
Boerekamps, Anne, Newsum, Astrid M, Smit, Colette, Arends, Joop E, Richter, Clemens, Reiss, Peter, Rijnders, Bart J A, Brinkman, Kees, van der Valk, Marc, and Cohort, NVHB-SHM Hepatitis Working Group and the Netherlands ATHENA HIV Observational
- Subjects
- *
THERAPEUTIC use of interferons , *ANTIVIRAL agents , *HEALTH services accessibility , *HEPATITIS C , *HIV infections , *HIV-positive persons , *EVALUATION of medical care , *MEDICAL care use , *INTRAVENOUS drug abusers , *DISEASE remission , *MEN who have sex with men , *DESCRIPTIVE statistics , *MIXED infections - Abstract
Background. The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV. Methods. Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response. Results. Of 23 574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14 and a pegylated interferon-alfa-based regimen had failed in 54. Conclusions. Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline.
- Author
-
Ammerlaan, Heidi S. M., Kluytmans, Jan A. J. W., Berkhout, Hanneke, Buiting, Anton, de Brauwer, Els I. G. B., van den Broek, Peterhans J., van Gelderen, Paula, Leenders, Sander (A.) C. A. P., Ott, Alewijn, Richter, Clemens, Spanjaard, Lodewijk, Spijkerman, Ingrid J. B., van Tiel, Frank H., Voorn, G. Paul, Wulf, Mireille W. H., van Zeijl, Jan, Troelstra, Annet, and Bonten, Marc J. M.
- Subjects
- *
METHICILLIN-resistant staphylococcus aureus , *PSEUDOMONAS fluorescens , *CARBOXYLIC acids , *DERMATOLOGIC agents , *DRUG resistance in microorganisms - Abstract
Background We evaluated the effectiveness of eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage in the Netherlands after the introduction of a guideline in 2006. The guideline distinguishes complicated (defined as the presence of MRSA infection, skin lesions, foreign-body material, mupirocin resistance and/or exclusive extranasal carriage) and uncomplicated carriage (not meeting criteria for complicated carriage). Mupirocin nasal ointment and chlorhexidine soap solution are recommended for uncomplicated carriers and the same treatment in combination with two oral antibiotics for complicated carriage. Methods A prospective cohort study was performed in 18 Dutch centres from 1 October 2006 until 1 October 2008. Results Six hundred and thirteen MRSA carriers underwent one or more decolonization treatments during the study period, mostly after hospital discharge. Decolonization was achieved in 367 (60%) patients with one eradication attempt and ultimately 493 (80%) patients were decolonized, with a median time until decolonization of 10 days (interquartile range 7–43 days). Three hundred and twenty-seven (62%) carriers were treated according to the guideline, which was associated with an absolute increase in treatment success of 20% [from 45% (91/203) to 65% (214/327)]. Conclusions Sixty percent of MRSA carriers were successfully decolonized after the first eradication attempt and 62% were treated according to the guideline, which was associated with an increased treatment success. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.